BRPI0509720A - derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina - Google Patents

derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina

Info

Publication number
BRPI0509720A
BRPI0509720A BRPI0509720-7A BRPI0509720A BRPI0509720A BR PI0509720 A BRPI0509720 A BR PI0509720A BR PI0509720 A BRPI0509720 A BR PI0509720A BR PI0509720 A BRPI0509720 A BR PI0509720A
Authority
BR
Brazil
Prior art keywords
alkyl
substituted
antagonist activity
alkanoyl
piperidine
Prior art date
Application number
BRPI0509720-7A
Other languages
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Beno T Christian Albert Boeck
Joseph Elisabeth Leenaerts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0509720A publication Critical patent/BRPI0509720A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE 4-ALQUIL- E 4-ALCANOIL-PIPERIDINA SUBSTITUìDA E SEU USO COMO ANTAGONISTAS DE NEUROCININA. A presente invenção refere-se a derivados de 4-alquil- e 4-alcanoil-piperidina substituída tendo atividade antagonista de neurocinina, em particular atividade antagonista de NKC~ 1~ e uma atividade antagonista combinada de NK~ 1~/NK~ 3~ composições contendo os mesmos e seu uso como medicamento, em particular para o tratamento e/ou profilaxia de esquizofrenia, êmese, ansiedade e depressão, síndrome do intestino irritável (IBS), distúrbios do ritmo circadiano, pré-eclâmpsia, nocicepção, dor, em particular dor visceral e neuropática, pancreatite, inflamação neurogênica. asma, doença pulmonar obstrutiva crónica (COPD) e distúrbios de micção tal como incontinência urinária. Os compostos de acordo com a invenção podem ser representados pela Fórmula geral (I) e compreendem também os sais de adição de ácido ou de base básica farmaceuticamente aceitáveis, as formas isoméricas dos mesmos, a forma N-óxido dos mesmos e pró-drogas dos mesmos, em que todos os substituintes são definidos como na reivindicação 1.
BRPI0509720-7A 2004-04-08 2005-04-04 derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina BRPI0509720A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101467 2004-04-08
PCT/EP2005/051509 WO2005097774A1 (en) 2004-04-08 2005-04-04 Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists

Publications (1)

Publication Number Publication Date
BRPI0509720A true BRPI0509720A (pt) 2007-09-25

Family

ID=34928945

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509720-7A BRPI0509720A (pt) 2004-04-08 2005-04-04 derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina

Country Status (23)

Country Link
US (1) US20070213346A1 (pt)
EP (1) EP1737838B1 (pt)
JP (1) JP2007532516A (pt)
KR (1) KR20070007347A (pt)
CN (1) CN1938291B (pt)
AR (1) AR048532A1 (pt)
AT (1) ATE396185T1 (pt)
AU (1) AU2005231986B2 (pt)
BR (1) BRPI0509720A (pt)
CA (1) CA2561967A1 (pt)
DE (1) DE602005007002D1 (pt)
EA (1) EA010312B1 (pt)
ES (1) ES2307169T3 (pt)
IL (1) IL178461A0 (pt)
JO (1) JO2525B1 (pt)
MX (1) MXPA06011683A (pt)
MY (1) MY142773A (pt)
NO (1) NO20065022L (pt)
NZ (1) NZ550098A (pt)
PA (1) PA8628901A1 (pt)
TW (1) TWI358298B (pt)
WO (1) WO2005097774A1 (pt)
ZA (1) ZA200608356B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1858887A1 (en) * 2005-02-23 2007-11-28 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
CA2757726A1 (en) 2009-04-02 2010-10-07 Shionogi & Co., Ltd. Acrylamide compounds and the use thereof
CN102369186B (zh) 2009-04-02 2014-07-09 默克专利有限公司 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物
EP2493871B1 (en) * 2009-10-30 2014-09-03 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
RU2673489C2 (ru) * 2013-09-12 2018-11-27 Ф. Хоффманн-Ля Рош Аг Производные индолкарбоксамида
SMT201900719T1 (it) * 2015-05-18 2020-01-14 Nerre Therapeutics Ltd Antagonista del recettore nk-1/nk-3 per il trattamento delle vampate di calore
AU2019233606B2 (en) 2018-03-14 2024-10-03 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists
EP3983369B1 (en) 2019-06-12 2023-08-02 Nouryon Chemicals International B.V. Process for the production of diacyl peroxides
JP7335362B2 (ja) 2019-06-12 2023-08-29 ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ 過酸化ジアシルを生成するためのプロセス
EP3983368B1 (en) 2019-06-12 2023-08-02 Nouryon Chemicals International B.V. Process for the production of diacyl peroxides
WO2020249689A1 (en) 2019-06-12 2020-12-17 Nouryon Chemicals International B.V. Process for the production of peroxyesters
EP3983340B1 (en) * 2019-06-12 2023-08-02 Nouryon Chemicals International B.V. Method for isolating carboxylic acid from an aqueous side stream
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
EP1578744B1 (en) * 2002-12-23 2008-07-09 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
PA8628901A1 (es) 2006-09-08
ATE396185T1 (de) 2008-06-15
IL178461A0 (en) 2007-02-11
AU2005231986A1 (en) 2005-10-20
CA2561967A1 (en) 2005-10-20
AR048532A1 (es) 2006-05-03
ZA200608356B (en) 2008-07-30
TWI358298B (en) 2012-02-21
CN1938291A (zh) 2007-03-28
KR20070007347A (ko) 2007-01-15
MY142773A (en) 2010-12-31
JP2007532516A (ja) 2007-11-15
EA200601880A1 (ru) 2007-02-27
CN1938291B (zh) 2011-11-16
ES2307169T3 (es) 2008-11-16
AU2005231986B2 (en) 2011-02-24
NZ550098A (en) 2009-10-30
DE602005007002D1 (de) 2008-07-03
US20070213346A1 (en) 2007-09-13
WO2005097774A1 (en) 2005-10-20
MXPA06011683A (es) 2006-12-14
NO20065022L (no) 2006-11-03
JO2525B1 (en) 2010-03-17
TW200603797A (en) 2006-02-01
EP1737838B1 (en) 2008-05-21
EP1737838A1 (en) 2007-01-03
EA010312B1 (ru) 2008-08-29

Similar Documents

Publication Publication Date Title
BRPI0509720A (pt) derivados de 4-alquil- e 4-alcanoil-piperidina substituìda e seu uso como antagonistas de neurocinina
US12312349B2 (en) Apoptosis-inducing agents
TW200604198A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
BR112021022099A2 (pt) Derivados de amino quinazolina como inibidores de p2x3
MY142090A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
BR0317658A (pt) Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina substituìda e seu emprego como antagonistas de neuroquinina
BR112014001801A2 (pt) indazóis
CL43596B (es) Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica.
MX350862B (es) Acidos de piperidinil naftilacetico.
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
WO2010091104A8 (en) Glucosylceramide synthase inhibitors
NZ591914A (en) Naphthylacetic acids
HRP20151338T1 (hr) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita
BRPI0608074A2 (pt) derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
AR078552A1 (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
CL2007002349A1 (es) Compuestos derivados de pirazolo[3,4-b]piridina; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de una enfermedad inflamatoria y/o alergica, tal como epoc, asma y rinitis.
BR112021020279A2 (pt) Derivados de piridopirimidinas como inibidores de p2x3
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
EA200701898A1 (ru) Производные диаза-спиро-[4.4]-нонана в качестве антагонистов нейрокинина (nk1)
EA200800183A1 (ru) Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения
MY145168A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
DE602005022558D1 (de) Mikroemulsionsformulierungen mit bestimmten substanz p antagonisten

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.